_^^^^^ Mathematical modeling combined with experiment has led to increased understanding of the processes that underlie HIV-1 infection the development of improved therapies. Nevertheless HIV has not eradicated from infected individuals. Here we propose to develop more realistic models of HIV infection and treatment that include coreceptor usage and effects of CCR5 blocking drugs. We will also analyze the dynamics of SIV and T cell populations in SIV infections in their natural hosts, which are nonpathogenic, in order to better understand the nature of HIV pathogenesis. Infection by hepatitis C virus (HCV) and hepatitis B virus (HBV) continue to cause liver failure and hepatocellular carcinoma in infected individuals. Understanding the basis of pathogenesis and the development of potent antiviral therapies for these viruses lag behind our advances in HIV. We propose to expand our efforts in modeling HCV and HBV in vivo kinetics and the effects of antiviral therapy. In the case of HCV we propose to develop realistic models of new treatments using ribavirin, pegylated interferon a2b, protease and polymerase inhibitors, as well as to understand the effects on infection on CD4+ and CD8+ T cell kinetics. For HBV we propose to both develop new dynamic models of infection as well as to examine with modeling the effectiveness of therapies involving combinations of antiviral agents. Our goal in all of these analyses is to gain basic understanding and help move that understanding into new treatments.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Project (R01)
Project #
5R01RR006555-17
Application #
7440237
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Chang, Michael
Project Start
1991-04-19
Project End
2009-06-30
Budget Start
2008-06-01
Budget End
2009-06-30
Support Year
17
Fiscal Year
2008
Total Cost
$307,697
Indirect Cost
Name
Los Alamos National Lab
Department
Type
DUNS #
175252894
City
Los Alamos
State
NM
Country
United States
Zip Code
87545
Arazi, Arnon; Pendergraft 3rd, William F; Ribeiro, Ruy M et al. (2013) Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches. Semin Immunol 25:193-200
Lau, Daryl T-Y; Negash, Amina; Chen, Jie et al. (2013) Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 144:402-413.e12
Huang, Xiaojie; Chen, Hui; Li, Wei et al. (2012) Precise determination of time to reach viral load set point after acute HIV-1 infection. J Acquir Immune Defic Syndr 61:448-54
Chaudhury, Srabanti; Perelson, Alan S; Sinitstyn, Nikolai A (2012) Spontaneous clearance of viral infections by mesoscopic fluctuations. PLoS One 7:e38549
Guedj, H; Guedj, J; Negro, F et al. (2012) The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat 19:488-96
Chatterjee, Anushree; Guedj, Jeremie; Perelson, Alan S (2012) Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther 17:1171-82
Bar, Katharine J; Tsao, Chun-yen; Iyer, Shilpa S et al. (2012) Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 8:e1002721
Giorgi, E E; Bhattacharya, T (2012) A note on two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics 68:1323-6; author reply 1326
Guedj, Jeremie; Dahari, Harel; Pohl, Ralf T et al. (2012) Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 56:1019-24
Nag, Ambarish; Monine, Michael; Perelson, Alan S et al. (2012) Modeling and simulation of aggregation of membrane protein LAT with molecular variability in the number of binding sites for cytosolic Grb2-SOS1-Grb2. PLoS One 7:e28758

Showing the most recent 10 out of 223 publications